FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer (PRODIGE 24 / CCTG PA.6) (2018)

Peer-Reviewed Study · Conroy T, Hammel P, Hebbar M, et al.; Canadian Cancer Trials Group and Unicancer-GI-PRODIGE · December 20, 2018

Conroy T et al., 2018-12-20: Phase 3 trial of modified FOLFIRINOX versus gemcitabine after resection of pancreatic ductal adenocarcinoma in 493 patients. Median overall survival was 54.4 versus 35.0 months; grade 3-4 adverse events occurred in 75.9% versus 52.9%.

The median overall survival was 54.4 months in the modified-FOLFIRINOX group and 35.0 months in the gemcitabine group (stratified hazard ratio for death, 0.64; 95% CI, 0.48 to 0.86; P=0.003).

p.2395 (Abstract, Results)

Conroy T et al., 2018-12-20: Phase 3 trial of modified FOLFIRINOX versus gemcitabine after resection of pancreatic ductal adenocarcinoma in 493 patients. Median overall survival was 54.4 versus 35.0 months; grade 3-4 adverse events occurred in 75.9% versus 52.9%. Funder (abstract): 'R&D Unicancer and others'; NCT01526135; EudraCT 2011-002026-52. No author disclosures in the MEDLINE record; drugs generic. Comparator: gemcitabine, not placebo. This is the strongest single counter-example to 'minimal impact' in pancreatic cancer: in resected disease adjuvant chemotherapy roughly doubles median survival. Study type: randomized trial.